Showing 1251-1260 of 3001 results for "".
- Evidence of Remyelination Seen in People with MS Receiving Combination Therapyhttps://practicalneurology.com/news/evidence-of-remyelination-seen-in-people-with-ms-receiving-combination-therapy/2483873/Combined treatment with metformin, a biguanide used to treat diabetes mellitus type 2, and clemastine, a antihistamine, may promote myelin repair in people with multiple sclerosis, according to results of the phase 2 CCMR-Two clinical trial (NCT05131828) presented at the 41st Congress
- FDA Delays Decision on Tolebrutinib for Non-Relapsing Secondary Progressive MShttps://practicalneurology.com/news/fda-delays-decision-on-tolebrutinib-for-non-relapsing-secondary-progressive-ms/2483482/The Food and Drug Administration (FDA) has extended its review period for tolebrutinib (Sanofi, Bridgewater, NJ), moving the Prescription Drug User Fee Act (PDUFA) decision date from September 28 to December 28, 2025. Tolebrutinib is an oral, brain-penetrant Bruton's tyrosine kinase (BTK) inhibit
- Guidelines for Use of Stem Cell Transplantation for Refractory MS and NMOSD Publishedhttps://practicalneurology.com/news/guidelines-for-use-of-stem-cells-for-refractory-ms-and-nmosd-published/2474472/A new consensus statement from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Society for Blood and Marrow Transplantation (EBMT) provides updated guidance on the use of autologous hematopoietic stem cell transplantation (AHSCT) in individuals d
- Data Regarding Tolebrutinib Treatment for Nonrelapsing Secondary Progressive MS Presented and Publishedhttps://practicalneurology.com/news/tolebrutinib-significantly-reduced-disability-progression-in-non-relapsing-secondary-progressive-multiple-sclerosis/2474048/Treatment with tolebrutinib (Sanofi, Bridgewater NJ), a Bruton’s tyrosine kinase (BTK) inhibitor, significantly delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS). The full set of results from the phase 3 HERCULES clinical trial (NCT04411
- Experimental BTK Inhibitor Suppressed Inflammatory Disease Activity in Those with Relapsing MShttps://practicalneurology.com/news/long-term-treatment-with-fenebrutinib-suppressed-inflammatory-disease-activity-in-relapsing-ms/2473796/Fenebrutinib (Roche, Basel, Switzerland), an investigational oral, reversible noncovalent Bruton tyrosine kinase (BTK) inhibitor, demonstrated significant efficacy in suppressing inflammatory disease activity in people with relapsing multiple sclerosis (RMS) according to the results of the open-l
- Subcutaneous Ocrevus Zunovo Approved as Treatment for Primary Progressive and Relapsing MShttps://practicalneurology.com/news/subcutaneous-ocrevus-zunovo-approved-as-treatment-for-primary-progressive-and-relapsing-ms/2470576/The Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq; Genentech, South San Francisco, CA) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is a subcutaneous formulation of
- Head-to-Head Comparison of Kesimpta vs Ocrevus Treatment in Patients with MShttps://practicalneurology.com/news/head-to-head-comparison-of-kesimpta-vs-ocrevus-treatment-in-patients-with-ms/2470485/Real-world study results presented at the 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) demonstrated similar persistence and adherence of Kesimpta (ofatumumab; Novartis, East Hanover, NJ) treatment compared with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA
- ~25% of Patients with MS Treated with Ocrevus Report Wearing-Off Phenomenonhttps://practicalneurology.com/news/25-of-patients-with-ms-treated-with-ocrevus-report-wearing-off-phenomenon/2470480/Study results presented at the 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) revealed that nearly 25% of people with multiple sclerosis (PwMS) being treated with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) experienced a wearing-off phenomenon (ie, a retu
- Unexpected Association Found Between Certain Beverages and MS Riskhttps://practicalneurology.com/news/unexpected-association-found-between-certain-beverages-and-ms-risk/2470155/A study from Iran published in the Journal of Health, Population and Nutrition found that drinki
- Serum Glial Fibrillary Acidic Protein as Biomarker for MS Progressionhttps://practicalneurology.com/news/serum-glial-fibrillary-acidic-protein-as-biomarker-for-ms-progression/2470110/Serum glial fibrillary acidic protein (sGFAP) concentrations are